Abstract
Summary
Fluoxymesterone, a C-17 methylated derivative of testosterone employed in the treatment of renal-failure patients with refractory anemia, was administered to Sprague-Dawley rats and the effects on plasma triglyceride (TG) and immunoreactive insulin (IRI) levels and the rate of hepatic triglyceride secretion (TGSR) into plasma determined (Triton). Animals treated with fluoxymesterone demonstrated significantly lower TG (<0.05) and no alteration in TGSR. These findings are consistent with other observations which suggest that the triglyceride-lowering effect of androgens results from an accelerated rate of removal of triglyceride-rich lipoproteins from plasma.
This study was supported by Contract 1-AM-3-2212 from the Kidney Disease Control Branch of the National Institute of Arthritis and Metabolic Diseases, and Grant HL 16219-01-A1 from the National Institutes of Health.
Get full access to this article
View all access options for this article.